Navigation Links
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Date:1/5/2012

RICHMOND, Calif., Jan. 5, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 7:30 am PT (10:30 am ET) on Thursday, January 12, 2012, at the 30th Annual J.P. Morgan Healthcare Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. Sangamo has ongoing clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.  Other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
6. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
7. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
8. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
9. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. Sangamo Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... of Hannah Holscher, PhD, RD, to its Scientific Advisory Board. Dr. Holscher is ... Nutrition and the Division of Nutritional Sciences at the University of Illinois Urbana-Champaign, ...
(Date:9/17/2019)... POWAY, Calif. (PRWEB) , ... September 17, 2019 , ... ... of osteoarthritis. At only four months old, Tucker was limping and lame on his ... hip and elbow dysplasia and it was called “the worst case the vet had ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for ... Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... educate about the latest developments in genome sequencing analysis. Check your local listings ... taking place at Rivermap Research & Consulting and will explore its revolutionary pathogenic ...
Breaking Biology Technology:
(Date:9/24/2019)... ... September 24, 2019 , ... A-Alpha Bio ... drug development, announced today that it has raised $2.8M from leading science-focused venture ... also includes AME Cloud Ventures, Boom Capital, Madrona Venture Group, Sahsen Ventures, Washington ...
(Date:9/17/2019)... ... ... VISTAAR released ADVISORY Playbooks to help small and mid-level companies who ... their internal strategies they formed for developing or launching new products or expanding to ... to change their product elements and want to know the impact, introducing new product ...
(Date:9/14/2019)... , ... September 12, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... company’s biologics business. Dr. Schaffer has played an integral advisory role on the ...
Breaking Biology News(10 mins):